Opko Licenses Kallikrein Proteins as Biomarkers for Prostate Cancer
January 30, 2012
Opko Licenses Kallikrein Proteins as Biomarkers for Prostate Cancer
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- IHT Begins Selling Opko's Protein Biomarker Prostate Cancer Dx
October 5, 2012 / ProteoMonitor - Opko Expands Prostate Cancer Biomarker Licensing Deal as Part of Commercialization Plan
March 23, 2012 / ProteoMonitor - Opko Acquires CLIA Lab
December 18, 2012 / GenomeWeb Daily News - Opko to Purchase OURLab CLIA Lab to Support US Launch of 4Kscore Prostate Cancer Dx
October 26, 2012 / ProteoMonitor - Opko Health Revamping Peptoid-Based Diagnostic Platform, Prepping Alzheimer's Test for Market
July 27, 2012 / ProteoMonitor